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Figure 1. An assay more sensitive than that used by Chirouze et al. [1] was used to measure the level of procalcitonin (PCT) and calcitonin
precursors in 101 patients admitted to a medical intensive care unit [3]. This assay can reliably detect low levels of PCT and calcitonin precursors in
healthy persons (i.e., control subjects). As illustrated, levels of PCT and calcitonin precursors in the control subjects were significantly lower than
those in nonbacteremic patients in a medical intensive care unit who had various degrees of systemic inflammatory response syndrome (SIRS; degrees
1–4 in severity) diagnosed ( between control subjects and the SIRS groups listed; there was no significant difference between the SIRSPp .001
groups). There is considerable separation of the latter patients from those with sepsis (horizontal line).
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Sir—We agree with Chirouze et al. [1]
that the measurement of procalcitonin
(PCT) levels is very useful for evaluating
the presence and extent of systemic infec-
tion in adult patients with acute fever.
Nevertheless, there are several issues raised
by their findings that require clarification.
It would be helpful if Chirouze et al.
[1] would have provided more details
about the reported wide range of PCT lev-
els (0.05–87 ng/mL) in the nonbacteremic
subjects. Many of the nonbacteremic sub-
jects (e.g., those with viral and skin infec-
tions) would be expected to have low PCT
levels. In addition, did the patients who
received previous antibiotic treatment
have relatively low levels of PCT? What
was the PCT level in patients with “tran-
sient bacteremia”?
With regard to the evaluation of low
levels of serum PCT, it must be recognized
that the PCT levels reported in most pub-
lished clinical studies, including that of
Chirouze et al. [1], were measured by an
assay that was unable to reliably measure
levels of !300 pg/mL. The importance of
such sensitivity was shown in a study of
patients in an intensive care unit in which
2 different assays were used in parallel [2].
Therefore, because any claim that a neg-
ative predictive value has been established
must be based on the results of an appro-
priately discriminating assay, the cutoff
value of 400 pg/mL suggested by Chirouze
et al. [1] was not clinically valid. To illus-
trate this point further, figure 1 shows the
range of PCT levels, as determined by a
sensitive assay (0.005 ng/mL), in healthy
subjects and in patients in an intensive
care unit [3] with various degrees of in-
flammation but without infection (i.e.,
systemic inflammatory responses syn-
drome [SIRS] 1–4). Clearly, PCT levels can
span a wide range of concentrations before
reaching the levels detected by the com-
monly used commercial assay used by
Chirouze et al. [1].
The role of serum PCT measurement
(which is more appropriately termed “cal-
citonin precursor measurement” [4]) in
the diagnosis of various inflammatory and
infectious illnesses is evolving, as Chirouze
et al. [1] suggested in their article. How-
ever, the time has arrived to apply sensitive
assays that can distinguish between PCT
levels in healthy individuals, nonbacter-
emic patients with escalating SIRS, and
bacteremic patients [5, 6]. Until this is
done, the reliance on PCT assays with
poor low-level sensitivity to predict the ab-
sence of bacteremia in adult patients with
acute fever is problematic.
Eric Nylen,1,2 Beat Muller,3
Kenneth L. Becker,1,2 and Richard Snider2
1Endocrinology Program, Department of Medicine,
George Washington University School of Medicine
and 2Veterans Affairs Medical Center, Washington,
D.C.; and 3Department of Endocrinology,
University Hospitals, Basel, Switzerland
References
1. Chirouze C, Schuhmacher H, Rabaud C, et al.
Low serum procalcitonin level accurately pre-
824 • CID 2003:36 (15 March) • CORRESPONDENCE
dicts the absence of bacteremia in adult patients
with acute fever. Clin Infect Dis 2002; 35:
156–61.
2. Whang KT, Steinwald PM, White JC, Sider RH,
Nylen ES, Becker KL. Serum calcitonin pre-
cursors in sepsis and systemic inflammation. J
Clin Endocrinol Metab 1998; 83:3296–301.
3. Muller B, Becker KL, Schachinger H, et al. Cal-
citonin precursors are reliable markers of sepsis
in a medical intensive care unit. Crit Care Med
2000; 28:977–83.
4. Snider RH, Nylen ES, Becker KL. Procalcitonin
and its component peptides in systemic inflam-
mation and sepsis: immunochemical investi-
gation. J Invest Med 1997; 45:552–60.
5. Nylen ES, Stryjewsky G, Snider RH, Patel K,
Becker KL, Dalton H. The utility of a sensitive
calcitonin precursor assay in febrile neutro-
penic children with leukemia [abstract 86]. In:
Programs and abstracts of the 10th International
Congress on Infectious Diseases (Singapore).
Boston: International Society for Infectious
Diseases, 2002:23.
6. Morgenthaler NG, Struck J, Fischer-Schultz C,
Seidel-Mueller E, Beier W, Bergmann A. De-
tection of procalcitonin (PCT) in healthy con-
trols and patients with local infection by a sen-
sitive ILMA. Clin Lab 2002; 48:263–70.
Reprints or correspondence: Dr. Eric Nylen, Endocrinology Pro-
gram, Dept. of Medicine, Veterans Affairs Medical Center,
50 Irving St. NW, Rm. GE246, Washington, DC 20422
(Nylen4@aol.com).
Clinical Infectious Diseases 2003; 36:823–4
 2003 by the Infectious Diseases Society of America. All
rights reserved. 1058-4838/2003/3606-0024$15.00
Procalcitonin: What Should
Be Its Role in the Clinical
Management of Febrile
Patients Admitted
to the Hospital?
Sir—I read with interest the article by
Chirouze et al. [1]. In their study, mea-
surement of serum procalcitonin (PCT)
levels helped differentiate bacteremic from
nonbacteremic infectious episodes in 165
acutely febrile patients admitted to the
hospital. On the basis of their findings,
Chirouze et al. [1] advocated routine mea-
surement of serum PCT levels as guidance
to determine whether or not to perform
multiple blood cultures for and administer
empirical antibiotic therapy to such
patients.
To offer such broad advice regarding the
clinical management of febrile patients on
the basis of one study is, however, pre-
mature. For instance, the association of
bacteremia at admission to the hospital
with the subsequent morbidity and in-
hospital death of patients with an acute
infection is not strong enough to justify
withholding empirical antibiotic treat-
ment to patients with low PCT levels. In
a study of 464 adult febrile patients ad-
mitted to the hospital, 90 patients had bac-
teremia and 33 patients died [2]. Of the
patients who died, only 10 were bacter-
emic at admission (relative risk of in-hos-
pital death due to bacteremia, 1.9; 95%
CI, 0.9–4.2) [2]. The circulating concen-
tration of proinflammatory microbial
components, rather than the presence of
whole, culturable bacterial cells, appeared
relevant to the prediction of the course
of disease. For example, of 48 patients
who had gram-negative bacteremia—
most cases of which were due to pyelo-
nephritis—7 (29%) of the 24 patients with
endotoxemia (endotoxin concentration
[as determined by Limulus amoebocyte
lysate assay], 15 pg/mL) died, whereas 0
of the 24 patients without endotoxemia
died ( ) [2]. Thus, the clinical con-P ! .01
dition of the patient and the likely source
of infection, rather than knowledge of the
presence or absence of bacteremia, will
dictate the administration of empirical an-
tibiotic therapy to, for example, patients
with pyelonephritis, erysipelas, cholangi-
tis, and so on. Finally, the use of serum
PCT levels as guidance for clinical man-
agement is premature because I could not
confirm the very high negative predictive
value of low PCT levels for determining
the absence of bacteremia in acutely febrile
patients.
I prospectively examined the associa-
tion between circulating levels of various
markers of infection in and clinical find-
ings and hospital outcome for adult febrile
patients who were included in previous
studies in which I participated [2, 3]. The
PCT levels of 381 patients (median age,
62 years; 59% male) were measured and
compared with the results of microbio-
logical analyses to validate the findings of
Chirouze et al. [1]. PCT levels were mea-
sured in a single run by use of an im-
munoluminometric assay (Brahms Diag-
nostica). The lower limit of detection of
the assay was 0.1 ng/mL. For 66 (17%) of
381 patients, blood cultures were positive
for bacteremia; gram-positive microor-
ganisms were grown in 35 cultures, gram-
negative microorganisms were grown in
28 cultures, and mixed growth occurred
in 3 cultures. Using the PCT cutoff value
of 0.4 ng/mL suggested by Chirouze et al.
[1], clinicians would have missed 10
(15%) of 66 episodes of bacteremia. Of
note, none of the 10 bacteremic patients
with PCT levels of !0.4 ng/mL had severe
liver disease, which was a suggested reason
that this PCT cutoff value was not noted
among bacteremic patients [1]. Alternate
cutoff values did not improve the asso-
ciation between low levels of PCT and the
absence of bacteremia (table 1); the neg-
ative predictive values were 88%–94% for
the different PCT cutoff values analyzed.
The negative predictive value of measure-
ment of low PCT levels for the detection
of endotoxemia was even lower (!80%),
although there was a trend toward an
association between a positive predictive
value of the measurement of low PCT lev-
els and detection of endotoxemia ( 2x p
). In one of the studies reported earlier,.06
I and colleagues [3] described a prediction
model of hospital outcome that reflected
a real-life encounter between physicians
and a febrile patient at admission to the
hospital. We reported that clinical data
(e.g., patient age, underlying disease, and
recent history with respect to the febrile
episode) outweighed the predictive value
of laboratory markers like cytokine and
PCT levels [3].
High levels of circulating markers of
infection (e.g., cytokines, C-reactive pro-
tein, and PCT) and a high erythrocyte sed-
imentation rate are generally associated
with the severity of the inflammatory re-
sponse and any adverse outcomes, and,
thus, they may be useful for the stratifi-
cation of patients in clinical studies. How-
ever, when compared with the value of
clinical judgment, the predictive value of
measuring these markers at admission to
identify patients who have an infection,
